



Clarification on resolution no. 6 forming part of Notice of the Annual General Meeting dated 23 April 2024:

One of the objects of the fund raised from IPO was towards achieving inorganic growth through acquisitions. In this regard and as part of our strategic objective to enhance our global footprint and drive long-term growth, we have established a subsidiary - Cyient DLM Inc. in the United States of America (US). The setting up of the subsidiary in the US will help us with better market understanding, customer relationships, and tailored marketing strategies. The subsidiary will also make acquisitions as needed. The incorporation of the subsidiary was disclosed to the exchanges on 07 March 2024 and the details of the same are provided in our Annual Report FY 2023-24.

The resolution for investment, loans and guarantees is primarily taken for the anticipated transactions between the Company and its subsidiaries.

We hereby confirm that the loans/guarantees given, and investments made will be made/ provided only to **Subsidiaries** which are part of promoter owned/ controlled entities.

As on 31 March 2024, the statutory limit available is Rs. 8.5 billion. We have requested approval from the shareholders for an additional Rs. 4.0 billion, in line with the expansion plans envisaged for the future, through our subsidiaries. The request to increase the limits by another Rs. 4.0 billion is crucial for us to capitalize on growth opportunities, expanding global footprint and achieve our strategic objectives of inorganic growth through making investments/ providing inter-corporate loans to our subsidiaries.